P2Y Receptor Antagonist

P2Y Receptor Antagonists (23):

Cat. No.	Product Name	Effect	Purity

HY-110322

PPTN hydrochloride	Antagonist	99.89%
PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a K_B value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity.

HY-108672

NF157	Antagonist
NF157 is a highly selective nanomolar P2Y11 antagonist with a pK_i of 7.35. The IC₅₀s are 463 nM, 1811 µM, 170 µM for P2Y11 (K_i=44.3 nM), P2Y1 (K_i=187 µM), P2Y2 (K_i=28.9 µM), respectively. NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA).

HY-110322A

PPTN	Antagonist	99.63%
PPTN is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a K_B value of 434 pM. PPTN exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity.

HY-101308A

MRS2179 tetrasodium hydrate	Antagonist	99.60%
MRS2179 tetrasodium hydrate is a competitive P2Y1 receptor antagonist, with a K_b of 102 nM and a pA₂ of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors. MRS2179 tetrasodium hydrate inhibits platelet aggregation.

HY-108658

MRS2500 tetraammonium	Antagonist	99.85%
MRS2500 tetraammonium is a potent, selective and stable antagonist of the P2Y1 receptor (K_i=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC₅₀ value of 0.95 nM. Antithrombotic activity.

HY-137955

MRS 2211 sodium hydrate	Antagonist
MRS 2211 sodium hydrate is a competitive P2Y13 receptor antagonist (pIC₅₀= 5.97). MRS 2211 sodium hydrate is highly selective to the P2Y13 receptor, showing more than 20-fold selectivity compared to the P2Y1 and P2Y12 receptors. MRS 2211 sodium hydrate can be used to further investigate the role of the P2Y13 receptor in different physiological and pathological processes, such as its function in blood cells, the nervous system and the immune system.

HY-109122

Selatogrel	Antagonist	99.75%
Selatogrel (ACT-246475) is a reversible and selective P2Y₁₂ receptor antagonist which inhibits platelet aggregation with an IC₅₀ of 8 nM. Selatogrel exhibits antithrombotic efficacy.

HY-111755

Oral antiplatelet agent 1	Antagonist
Oral antiplatelet agent 1 is a potent P2Y₁₂ receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC₅₀ value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders.

HY-172181

NSC380324	Antagonist
NSC380324 is a P2Y₁₂ receptor antagonist, possessing antiplatelet activity, and can be utilized in research on atherosclerotic cardiovascular diseases.

HY-103064

2-Methylthio-AMP sodium	Antagonist
2-Methylthio-AMP sodium is a selective and direct P2Y₁₂ antagonist. 2-Methylthio-AMP sodium is an inhibitor of ADP-dependent platelet aggregation.

HY-168139

MRS4865	Antagonist
MRS4865 (compund 7a) is a chimera of a P2Y14 receptor antagonist and a UDP-glucose agonist that protects against neuropathic pain.

HY-103055

PPTN mesylate	Antagonist
PPTN mesylate is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a K_B value of 434 pM. PPTN mesylate exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity.

HY-172417

Becondogrel	Antagonist
Becondogrel (2-Oxoclopidogrel) is the metabolite of Clopidogrel (HY-15283). Becondogrel irreversibly inhibits P2Y12 receptor, thereby inhibiting platelet aggregation and thrombosis.

HY-117572

MRS2567	Antagonist
MRS2567 is a P2Y receptor antagonist with the activity of inhibiting contraction of mouse mesenteric arteries. MRS2567 can inhibit the sustained contraction caused by UTP and UDP, and inhibit the Na⁺, K⁺, 2Cl^- co-transport-dependent signaling pathway, thereby affecting the myogenic tone of mouse mesenteric arteries.

HY-108665

AR-C66096 tetrasodium	Antagonist
AR-C66096 tetrasodium is a selective platelet P2Y_T receptor antagonist. AR-C66096 tetrasodium effectively blocks ADP-induced platelet aggregation. AR-C66096 tetrasodium can be used in the research of thromboembolism.

HY-122048

AR-C67085	Antagonist
AR-C67085 (PSB 0413; FPL 67085) is a potent platelet P_2T receptor antagonist with an pIC₅₀ value of 8.60. AR-C67085 inhibits ADP-induced platelet aggregation.

HY-136501

MRS2395	Antagonist
MRS2395, an dipivaloyl derivative, is a potent P2Y12 receptor antagonist. MRS2395 inhibits ADP-induced platelet activation with a K_i of 3.6 μM. MRS2395 inhibits cAMP induced by ADP in rat platelets in the presence of PGE1 with an IC₅₀ of 7 µM. MRS2395 enhances platelet dense granule release in response to TRAP-6.

HY-163645

P2Y12 antagonist 1	Antagonist
P2Y12 antagonist 1 (compound 26) is a P2Y12 receptor antagonist with a Ki of 3.13 μM. P2Y12 antagonist 1 can be used to inhibit platelet aggregation and is a potential antithrombotic agent.

HY-10064R

Ticagrelor (Standard)	Antagonist
Ticagrelor (Standard) is the analytical standard of Ticagrelor. This product is intended for research and analytical applications. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.

HY-10064S1

Ticagrelor-d₄	Antagonist
Ticagrelor-d₄ (AZD6140-d₄) is deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.

Name
Email *

	Sorry, but the email address you supplied was invalid.